Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Top-line Data from Pivotal SORAYA Trial on Track for Q4 Release Continued Progress in Ongoing MIRASOL, IMGN632, and IMGC936
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 15, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on June 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
WALTHAM, Mass. --(BUSINESS WIRE)--May 20, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
Results to be Presented in an Oral Session at 2021 ASCO Annual Meeting Combination Demonstrates Strong Anti-Tumor Activity in Patients with High FRα Expression, with a Confirmed Overall Response Rate of 64%, Median Duration of Response of 11.8 Months and Median Progression-Free Survival of 10.6
Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer Expected in the Fourth Quarter of 2021 FORWARD II Mirvetuximab Plus Avastin ® Doublet Cohort in Recurrent Ovarian Cancer, Regardless of Platinum Status, Selected for Oral Presentation at ASCO Preclinical Data
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 26, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, May 10, 2021 to discuss its first
First-in-Class ADAM9-Targeting ADC Demonstrates Anti-Tumor Activity in Multiple Solid Tumor Models WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 10, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that a